The present invention relates to the identification of the molecular
binding domains between presenilins and its substrates such as amyloid
precursor protein and telencephalin. These binding domains can be
efficiently used in drug screening assays to screen for compounds capable
of modulating the interaction between presenilins and type I
transmembrane proteins. The invention further relates to compounds
capable of modulating the interaction.